h1-hero-img

See all the benefits of hemolysis detection at the point of care

people-discussing

Enhance patient care and control costs

Whole blood hemolysis detection can help:

  • Reduce inappropriate patient management1–3
  • Increase patient satisfaction2,4
  • Optimize staff/nursing time3–5
  • Reduce costs2,4,5
Group_11

Improve clinical decision-making

Undetected hemolysis can impact patient care and costs

  • Hemolysis is the #1 source of preanalytical error1,6
  • Hemolysis accounts for up to 70% of all preanalytical errors7
  • Hemolysis elevates potassium (K+) by up to 152%8

Ensuring sample quality across the most common preanalytical errors, GEM Premier 7000* with iQM3 supports expedited decision-making and enhanced patient care and efficiency.

Group 376

Improve operational efficiency

GEM Premier 7000 and GEMweb® Plus 500 Custom Connectivity provide a total streamlined solution

  • STAT turnaround time in Core Laboratory can require 60 minutes9
  • Results with hemolysis detection in just 45 seconds at the point of care10

By reducing time to results with hemolysis detection; automating labor- and skill-intensive processes; and centralizing management, the GEM Premier 7000 with iQM3 can help improve operational efficiency.

table

Reduce costs

GEM Premier 7000 with iQM3 can support cost-reduction efforts

In addition to the clinical savings with whole blood hemolysis detection at point of care, the GEM Premier 7000 can help reduce costs associated with inventory and labor hours.11

table

Added benefits from Werfen

  • On-site preanalytical training and consulting
  • Analyzer software upgrades
  • Installation and validation of GEM Premier 7000
  • User training
  • CEU Education and on-site consultation from our experts

Discover the power of whole blood hemolysis detection

Request a custom value analysis report for your hospital

GEM, Premier, GEM Premier ChemSTAT, ChemSTAT, GEMweb, iQM, Hemochron, VerifyNow, Avoximeter, and ROTEM are trademarks of Instrumentation Laboratory Company (d.b.a. Werfen) and/or one of its subsidiaries or parent companies and may be registered in the United States Patent and Trademark Office and in other jurisdictions. The Werfen logo is a trademark of Werfen and may be registered in the Patent and Trademark Offices of jurisdictions throughout the world. All other product names, company names, marks, logos, and symbols are trademarks of their respective owners.

©2025 Instrumentation Laboratory. All rights reserved.

*Not available in all countries.

References: 

  1. O’Hara M, Wheatley EG, Kazmierczak SC. The impact of undetected in vitro hemolysis or sample contamination on patient care and outcomes in point-of-care testing: a retrospective study. J Appl Lab Med. 2020;5(2):332-341. doi:10.1093/jalm/jfz020.
  2. Phelan MP, Hustey FM, Good DM, Reineks EZ. Seeing red: blood sample hemolysis is associated with prolonged emergency department throughput. J Appl Lab Med. 2020;5(4):732–737. doi:10.1093/jalm/jfaa073.
  3. Wilson M, Adelman S, Maitre JB, et al. Accuracy of hemolyzed potassium levels in the emergency department. West J Emerg Med. 2020;21(6):272–275. doi:10.5811/westjem.2020.8.46812.
  4. Milutinović D, Andrijević I, Ličina M, Andrijević L. Confidence level in venipuncture and knowledge on causes of in vitro hemolysis among healthcare professionals. Biochem Med. 2015;25(3):401–409. doi:10.11613/BM.2015.040.
  5. Phelan MP, Ramos C, Walker LE, et al. The hidden cost of hemolyzed blood samples in the emergency department. J Appl Lab Med. 2021;6(6):1607–1610. doi:10.1093/jalm/jfab035.
  6. Lippi G, von Meyer A, Cadamuro J, Simund A-M. Blood sample quality. Diagnosis. 2018;6(1):25–31. doi:10.1515/dx-2018-0018.
  7. Lippi G, Salvagno GL, Favaloro EJ, Guidi GC. Survey on the prevalence of hemolytic specimens in an academic hospital according to collection facility: opportunities for quality improvement. Clin Chem Lab Med. 2009;47(5):616–618. doi:10.1515/CCLM.2009.132.
  8. Lippi G, Fontana R, Avanzini P, Sandei F, Ippolito L. Influence of spurious hemolysis on blood gas analysis. Clin Chem Lab Med. 2013;51(8):1651–1654. doi:10.1515/cclm-2012-0802.
  9. Wu AHB, Peacock WF. Potential medical impact of unrecognized in vitro hypokalemia due to hemolysis: A case series. Clin Chem Lab Med. 2024;62(10):1975-1979. doi:10.1515/cclm-2024-0351.
  10. Werfen. GEM Premier 7000 with iQM3 Operators Manual. P/N 00000026407. Rev 00. Aug 2023.
  11. Werfen. Enhancing patient care while controlling costs. G7K VAC PAK WW. Rev 00.

© Copyright 2025 All Rights Reserved